Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediWoundMDWD +3.21%57 Debt-to-Equity is 0.20 as of Mar. 2026, which is 5% above its 10-year median of 0.19. GuruFocus rates MDWD with a GF Score™ of 57/100 and a GF Value™ of $12.64 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 965 Biotechnology companies, MediWound ranks worse than 54.2% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for MediWound's Debt-to-Equity or its related term are showing as below:
MDWD'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.81 Med: 0.19 Max: 0.76
Current: 0.2
During the past 13 years, the highest Debt-to-Equity Ratio of MediWound was 0.76. The lowest was -1.81. And the median was 0.19.
MDWD's Debt-to-Equity is ranked worse than 54.2% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs MDWD: 0.20
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
MediWound Debt-to-Equity Related Terms
MediWound Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for MediWound's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDWD vs UNCY, ARCT, NGEN: Debt-to-Equity Comparison
For the Biotechnology subindustry, MediWound's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediWound Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MediWound's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where MediWound's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediWound (MDWD) has a Debt-to-Equity of 0.20 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MediWound and its competitors. This is near median its historical median of 0.19. According to the industry distribution chart, MediWound ranks #523 out of 965 companies in the Biotechnology industry, placing it in the top 54.2%.
Is MediWound's Debt-to-Equity too high?
MediWound's current Debt-to-Equity of 0.20 is near median its 10-year median of 0.19. The Biotechnology industry median Debt-to-Equity is 0.16. MediWound's value of 0.20 is 25% above this industry median. Based on the distribution chart, MediWound ranks #523 out of 965 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MediWound has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediWound's Debt-to-Equity compare to UNCY and ARCT?
According to the Biotechnology industry distribution chart, MediWound ranks #523 out of 965 companies for Debt-to-Equity. This places MediWound in the lower half of its industry. The industry median Debt-to-Equity is 0.16. MediWound's value of 0.20 is 25% above this benchmark. While the company's 10-year median is 0.19 vs. the industry median of 0.16, MediWound has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediWound's current Debt-to-Equity of 0.20 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MediWound and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediWound's current Debt-to-Equity is 0.20, which is near median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediWound stock overvalued right now?
Based on GuruFocus' analysis, MediWound (MDWD) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.64, compared to a current price of $14.61 — trading 15.6% above its estimated fair value. The current Debt-to-Equity is 0.20, which is near median its 10-year median of 0.19 and 25% above the Biotechnology industry median of 0.16. MediWound's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For MediWound (MDWD), the current Debt-to-Equity is 0.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediWound (MDWD) Overvalued in 2026?
Based on GuruFocus' analysis, MediWound stock appears to be overvalued.
The current stock price of $14.61 is trading 15.6% above its estimated GF Value™ of $12.64.
GuruFocus considers MediWound to be Modestly Overvalued.
Key valuation signals for MDWD:
Debt-to-Equity: 0.20 (near median its 10-year median of 0.19)
GF Value™: $12.64 vs. price of $14.61 (15.6% above fair value)
Industry Position: 25% above the Biotechnology median (#523 of 965)
No single metric tells the full story. See the MDWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
57GF Score
Get the complete analysis for MDWD
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDWD has been successfully added to your 
